Cargando…
Cisplatin Decreases ENaC Activity Contributing to Renal Salt Wasting Syndrome
Cisplatin (CDDP) is an important anticancer drug. A common side effect of CDDP is renal salt and water-wasting syndrome (RSWS). The origin of RSWS is obscure. Emerging evidence, though, suggests that broad inhibition of sodium transport proteins by CDDP may result in decreases in tubular reabsorptio...
Autores principales: | Soares, Antonio G., Mironova, Elena, Archer, Crystal R., Contreras, Jorge, Stockand, James D., Abd El-Aziz, Tarek Mohamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464492/ https://www.ncbi.nlm.nih.gov/pubmed/32752278 http://dx.doi.org/10.3390/cancers12082140 |
Ejemplares similares
-
P2Y(2) receptor decreases blood pressure by inhibiting ENaC
por: Soares, Antonio G., et al.
Publicado: (2023) -
Optogenetic Control of PIP2 Interactions Shaping ENaC Activity
por: Abd El-Aziz, Tarek Mohamed, et al.
Publicado: (2022) -
The role of the epithelial Na(+) channel (ENaC) in high AVP but low aldosterone states
por: Stockand, James D.
Publicado: (2012) -
ENaC in Salt-Sensitive Hypertension: Kidney and Beyond
por: Pitzer, Ashley L., et al.
Publicado: (2020) -
The N terminus of α-ENaC mediates ENaC cleavage and activation by furin
por: Kota, Pradeep, et al.
Publicado: (2018)